{"id":"NCT00440050","sponsor":"Alzheimer's Disease Cooperative Study (ADCS)","briefTitle":"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease","officialTitle":"A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2007-02-26","resultsPosted":"2010-08-30","lastUpdate":"2014-09-25"},"enrollment":402,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"DHA (Docosahexaenoic Acid)","otherNames":["Neuromins"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1.","type":"EXPERIMENTAL"},{"label":"2.","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease (AD).","primaryOutcome":{"measure":"Rate of Change on the ADAS-Cog 11.","timeFrame":"Baseline, 6, 12, 18 months","effectByArm":[{"arm":"Placebo","deltaMin":7.98,"sd":9.84},{"arm":"Docosahexaenoic Acid (DHA)","deltaMin":8.27,"sd":8.9}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":9},"locations":{"siteCount":51,"countries":["United States"]},"refs":{"pmids":["15041028","14745067","12873849","11935973","15339646","15788759","27358067","21045096"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":164},"commonTop":["other","fall","agitation","urinary tract infection","diarrhea"]}}